{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:01:54Z","timestamp":1790049714833,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106539","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T19:54:44Z","timestamp":1747684484000},"page":"106539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ocrelizumab for pediatric relapsing multiple sclerosis"],"prefix":"10.1016","volume":"100","author":[{"given":"Raed","family":"Alroughani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"AlMojel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasem","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Farouk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106539_bib0001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2229-3485.106403","article-title":"Pediatric clinical trials","volume":"4","author":"Bavdekar","year":"2013","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.msard.2025.106539_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.5566","article-title":"Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis","author":"Benallegue","year":"2024","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0003","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2023.01.011","article-title":"Ocrelizumab in pediatric multiple sclerosis","volume":"43","author":"Bibino\u011flu Amirov","year":"2023","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0005","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0883073812452784","article-title":"Pediatric multiple sclerosis","volume":"27","author":"Bigi","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0006","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.59.7.1006","article-title":"UBC MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106539_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of Fingolimod versus Interferon beta-1a in pediatric Multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106539_bib0008","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1212\/WNL.0000000000002884","article-title":"Pediatric multiple sclerosis: escalation and emerging treatments","volume":"87","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106539_bib0009","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0b013e318288694e","article-title":"International Pediatric MS Study Group Clinical Trials Summit: meeting report","volume":"80","author":"Chitnis","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106539_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106539_bib0011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106539_bib0012","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/1744666X.2017.1360135","article-title":"An update on multiple sclerosis in children: diagnosis,therapies, and prospects for the future","volume":"13","author":"Gordon-Lipkin","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106539_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106539_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/1352458517732843","article-title":"Therapy of highly active pediatric multiple sclerosis","volume":"25","author":"Huppke","year":"2019","journal-title":"Mult. Scler. J"},{"issue":"1","key":"10.1016\/j.msard.2025.106539_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106539_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0017","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106539_bib0018","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2011.08.001","article-title":"Disease activity free status in MS","volume":"1","author":"Lublin","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106539_bib0019","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-019-0592-z","article-title":"Newer treatment approaches in pediatric-onset multiple sclerosis","author":"Macaron","year":"2019","journal-title":"Curr. Treat. Options. Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2023.04.020","article-title":"U.S. Network of Pediatric Multiple Sclerosis Centers. Demographic features and clinical course of patients with pediatric-onset multiple sclerosis on newer disease-modifying treatments","volume":"145","author":"Malani Shukla","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2025.106539_bib0021","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737175.2022.2064743","article-title":"Pediatric multiple sclerosis: developments in timely diagnosis and prognostication","volume":"22","author":"Margoni","year":"2022","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.msard.2025.106539_bib0022","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.1212\/WNL.0000000000008667","article-title":"Determinants of quality of life in pediatric- and adult-onset multiple sclerosis","volume":"94","author":"McKay","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106539_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104942","article-title":"Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: a real-life observational study","volume":"79","author":"Moreau","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106539_bib0024","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. Available online at: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5\u00d711.pdf (Accessed 8 March 2020)."},{"key":"10.1016\/j.msard.2025.106539_bib0025","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1212\/NXI.0000000000001008","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the united kingdom","volume":"8","author":"OA","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106539_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106539_bib0027","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiplesclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"25","key":"10.1016\/j.msard.2025.106539_bib0028","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106539_bib0029","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1212\/NXI.0000000000000309","article-title":"B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis","volume":"4","author":"Schwarz","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2025.106539_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S2352-4642(24)00047-6","article-title":"Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries","volume":"8","author":"Sharmin","year":"2024","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.msard.2025.106539_bib0031","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0022-510X(11)70010-7","article-title":"Multiple sclerosis in childhood and adolescence","volume":"311","author":"Tenembaum","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106539_bib0032","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thomson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106539_bib0033","series-title":"Medication Guide Ocrevus","year":"2009"},{"issue":"9","key":"10.1016\/j.msard.2025.106539_bib0034","article-title":"Pediatric multiple sclerosis clinical features and outcome","volume":"87","author":"Waldman","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2025.106539_bib0035","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awp278","article-title":"Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis","volume":"132","author":"Yeh","year":"2009","journal-title":"Brain"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:09:22Z","timestamp":1754003362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S2211034825002810"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106539","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab for pediatric relapsing multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106539"}}